EHMT2 and metabolic dysfunction-associated steatotic liver disease: Hence, our study, on one hand, signifies the therapeutic potential of G9a that can be tested in preclinical models of NAFLD and on the other hand, highlight the need to understand the loci-specific recruitment of G9a and sequence-specific regulation of G9a by mTORC1 for better understanding of the disease outcome in lipotoxicity.